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of intranasal meperidine than by intermittent subcutaneous meperidine injections. The disadvantage of intranasal meperidine is its unpleasant taste if it runs down into
Intranasal meperidine self-administration as performed in the present study has not been described previously. Nasal opioid titration in this study was also performed for longer periods (up to 12 hr) than those reported elsewhere.
Methods
This prospective, randomized study was approved by the local ethics committee, and the patie.nts gave their written informed consent. Forty-four ASA physical status, I, II or III patients submitted to an orthopaedic operation under general anaesthesia were studied for 12 hr in a postanaesthetic care unit on the ftrst day atter surgery.
Twenty-two patients had free access to intranasal meperidine (nasal group) in a spray bottle with a premetered puff. One puff corresponded to 0.09 ml, which equals 4.5 mg of the commercially available meperidine solution (50 mg. ml-I). The patients could administer up to six nasal puffs per dose (27 mg meperidine) and were instructed to walt at least ten minutes between individual doses. Within these limitations, the patients were allowed to titrate nasal meperidine as individually required to achieve satisfactory pain relief. The patients were supervised by an observer during the study period.
The 22 patients of the control group received intermittent sc meperidine injections (25 or 50 mg) on request (sc group). This is the standard analgesic regimen in our postanaesthetic care unit. This standard pain management was performed by the nurse/doctor on the ward.
Exclusion criteria were analgesic abuse, current or fort mer opioid addiction, allergy to meperidine or problems with the nasal mucosa.
The study involved continuous noninvasive recording of the following variables: heart rate, respiratory rate and arterial haemoglobin oxygen saturation (Biox 3.700, Fa. Ohmeda). The data were documented at 30-min intervals. In addition, arterial blood pressure (Riva Rocci's method) and subjective pain intensity rated on a 101-point scale (0 = no pain, 100 = worst pain possible) were likewise evaluated at 30-min intervals. The rating scale for pain evaluation was explained to the patient on the day before surgery.
At each evaluation point, patients were asked about possible side effects such as nausea, vomiting, itching, diaphoresis, euphoria, dysphoria, nasal problems, etc. The ftrst meperidine dose was given at the patient's request. The inital pain intensity was the one evaluated prior to the first dose.
At the end of the observation period, the patients were given a questionnaire to rate their satisfaction with the method of pain management experienced. The categories were: excellent, good, satisfactory, bad, very bad, unacceptable. Patients were also asked to list the advantages and disadvantages.
The Mann-Whitney-U test for independent samples was used for the evaluation of statistically significant intergroup differences. Time-dependent intragroup changes were assessed using the Wilcoxon test for matched samples. A significant intergroup difference was assumed at P < 0.05. A nominal value of P < 0.0073 was necessary to achieve a true intragroup significance level ofp < 0.05 after 20 (Figure) repeated tests. 8
Results
There were no intergroup differences in the patients' age, height, weight or type of surgery (Table I) , nor was there any intergroup difference in the initial pain intensity. The There were no clinically important intergroup differences in cardiovascular and pulmonary variables. Four of the 22 patients in the nasal group complained of a bitter and burning taste in the naso-and/or oropharynx. Two patients in each group complained of nausea and vomiting.
Twenty-one of the 22 patients in the nasal group and 15 of the 22 in the sc group completed the final questionnaire (Table II) . The advantages and disadvantages of the pain management experienced by the patients are listed in Table III . There were no differences between groups.
Discussion
The present study demonstrates that better analgesia was achieved at most evaluation points by intranasal selfadministration of meperidine than by intermittent sc meperidine injections.
In previous studies on intranasal opioid administration, dosing was performed by the investigator, 2,3,6 whereas, in the present study, it was self-administered by the patients. This presented no problem to any patient. The availability of a powerful and quick-acting analgesic is beneficial to the patients and makes them independent of the ward staff. This seems to be the greatest advantage of intranasal self-administration. The fact that the overall satisfaction in the nasal group was not better than in the sc group may be due to two major reasons. Firstly, the study was performed in the postanaesthetic care unit, which has a high nurse-to-patient ratio. Therefore, patients asking for an analgesic received it quickly. Several studies have demonstrated that conventional (e.g., ira) opioid administration could be as effective as/v PCA. 9-u However, most wards experience difficulties with these conventional modes of opioid administration. Kuhn et al. ~2 reported a median of two hr between requesting and receiving an analgesic. Secondly, four patients in the nasal group reported a bitter and burning taste in the naso/oropharynx which may have been due to some of the intranasally administered meperidine running down the back of the throat. A similar problem is associated with nasal administration of the bitter-tasting substance midazolam, which causes a high percentage of children to cry. 13 However, other intranasally administered opioids such as fentanyl, sufentanil or morphine do not irritate the nasal or pharyngeal musosa. 2-5,7 An alternative long-lasting, fast-acting opioid other than meperidine would be desirable for nasal administration. A lipophilic opioid which easily penetrates biological membranes would be ideal. The mean amount of meperidine used was no greater in the nasal than in the sc group. Randomized, prospective and double-blind clinical studies by Striebel et al. suggest a high bioavailability of intranasal fentanyl and meperidine, the intranasal dose being approximately 1.51 times that of/v fentanyl and 1.36 times that of/v meperidine. 2, 6 The meperidine consumption in the present study is in accordance with the mean value of 175.1 ~xg-kg-lhr -t, 147.1 mg-70 kg -l. 12 hr -I reported by Lehmann.~4 However, other studies have demonstrated a higher meperidine requirement. 15-R7 The wide interindividual variation in opioid requirement observed in this study after intravenous and intranasal opioid administration is a well-known phenomenon. 2 meperidine. 6 As pain evaluations were performed at 30-min intervals in the present study, it was not possible to demonstrate the rapid onset of pain relief after intranasal meperidine. However, 11 of 21 patients in the nasal group specified the rapid onset of action as an advantage of nasal meperidine. Due to its rapid and powerful analgesic effect, the risk of overdosing and respiratory depression exists if the patients do not follow instructions closely regarding the dosing interval and the number of puffs per dose. A special spray bottle would therefore be desirable to ensure the same safety for intranasal opioid administration as for intravenous PCA. One drawback of the present study is the fact that neither the patients nor the observer were blinded to the tyiae of treatment. The results should therefore be confLrmed by a double-blind study, possibly including a comparison with/v PCA.
In conclusion, the present study demonstrates the strong and rapid analgesic effect of intranasal meperidine self-administration. The reduction of pain intensity achieved was greater in the nasal than in the sc group at most evaluation points. The nasal route of opioid administration was well accepted by most patients, a disadvantage of meperidine thus applied being its bitter and burning taste. A tasteless, long-lasting and quick-acting opioid would be desirable. It would also be preferable to have a special spray bottle with safety features comparable with those of an/v PCA device.
